Results 91 to 100 of about 562,472 (163)

Differential effects of sodium oxybate and baclofen on EEG, sleep, neurobehavioral performance, and memory

, 2012
Sodium oxybate (SO) is a GABAβ agonist used to treat the sleep disorder narcolepsy. SO was shown to increase slow wave sleep (SWS) and EEG delta power (0.75-4.5 Hz), both indexes of NREM sleep (NREMS) intensity and depth, suggesting that SO enhances ...
Schwartz, S., Lecciso, G., Constantinescu, Irina Oana, Vienne, Julie, Franken, P., Constantinescu, I., Vienne, J., Tafti, M., Heinzer, Raphael, Franken, Paul, Schwartz, Sophie, Heinzer, R., Lecciso, Gianpaolo, Tafti, Mehdi   +13 more
core   +1 more source

Pharmacokinetics and formulation selection of FT218, an investigational controlledrelease sodium oxybate formulation designed for once nightly dosing

, 2019
Introduction: Sodium oxybate is indicated for the treatment of Excessive Daytime Sleepiness (EDS) and cataplexy in patients with narcolepsy. The currently marketed product, an immediate release (IR) sodium oxybate is required to be taken twice nightly ...
Monteith, D, Roth, Thomas, Grassot, J, Castellan, C   +3 more
core   +1 more source

Sodium oxybate-a new horizon for symptomatic treatment of RBD? [PDF]

Sleep, 2023
Stefani A, Högl B, Videnovic A.
europepmc   +1 more source

Recent Advances and Emerging Pharmacotherapeutic Approaches for Central Hypersomnolence Disorders

Clinical Pharmacology: Advances and Applications
Katyayini Aribindi,1 Tanwe C Shende,1,2 Timothy E Albertson11Department of Internal Medicine – Division of Pulmonary, Critical Care & Sleep Medicine, University of California – Davis, Sacramento, CA, USA; 2Department of Medicine, Veterans Affairs ...
Aribindi K, Shende TC, Albertson TE
doaj  

Treatment with Sodium Oxybate in Children and Young Adults – a Register Study in Halland and Västra Götaland

, 2016
Background: Narcolepsy is a chronical neurological disease with a prevalence of 0,02-0,05 % in the western world. A massive increase in incidence occurred after the vaccination with Pandemrix against the H1N1-influenza.
Björck, Per
core  

Compatibility studies of Sodium oxybate oral solution

, 2019
Nātrija oksibutirāta orālā šķīduma savietojamības pētījumi. Valtere L. K., darba vadītāji Dr. ķīm., prof. Vīksna A., Mg. ķīm. Kuprevičs K., bakalaura darbs, 68 lappuses, 33 literatūras avoti, 4 pielikumi. Latviešu valodā. Darbā tika veikti savietojamības
Valtere, Līva Klinta
core  

Treatment cost of narcolepsy with cataplexy in Central Europe

Therapeutics and Clinical Risk Management, 2016
Petra Maresova,1 Michal Novotny,2,3 Blanka Klímová,4 Kamil Kuča3,51Department of Economics, Faculty of Informatics and Management, 2Department of Chemistry, Faculty of Science, University of Hradec Králové, 3Biomedical ...
Maresova P, Novotny M, Klímová B, Kuča K   +3 more
doaj  

A historical overview of the cardiovascular safety of sodium oxybate: clinical trials, clinical experience. [PDF]

Sleep Adv
Kushida CA.
europepmc   +1 more source

Pharmacokinetics and dose proportionality of FT218, an investigational controlled release formulation of sodium oxybate for once nightly dosing

, 2019
Introduction: Sodium oxybate is indicated for the treatment of Excessive Daytime Sleepiness (EDS) and cataplexy in patients with narcolepsy. The currently marketed product, an immediate release (IR) sodium oxybate, is required to be taken twice nightly ...
Monteith, D, Roth, Thomas, Grassot, J, Castellan, C   +3 more
core   +1 more source

Sleep-related eating disorder after dose escalation of sodium oxybate in narcolepsy type 1. [PDF]

J Taibah Univ Med Sci
Al Mazyad RA, Alhajaji R, Dhafar HO, BaHammam AS.   +3 more
europepmc   +1 more source